Cover Image
市場調查報告書

角膜乾燥症 (乾眼症) :開發中產品分析

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 219724
出版日期 內容資訊 英文 201 Pages
訂單完成後即時交付
價格
Back to Top
角膜乾燥症 (乾眼症) :開發中產品分析 Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 201 Pages
簡介

乾眼症症候群同時也被稱之為乾性角結膜炎(KCS)或乾燥角膜炎,是淚液及眼睛表面的多因子疾病。由於眼睛表面的潛在性損傷造成不適感、視覺障礙、淚液層不穩定性。常見的症狀有眼睛疲勞、畏光刺眼、充血等。危險因子除了年齡之外,還有可能因雷射眼科手術、藥劑等因素所造成。

本報告提供角膜乾燥症 (乾眼症) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

角膜乾燥症 (乾眼症)的概要

治療藥的開發

  • 開發中產品的概要

角膜乾燥症 (乾眼症) :企業開發中的治療藥

角膜乾燥症 (乾眼症) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

角膜乾燥症 (乾眼症) :企業開發中的產品

角膜乾燥症 (乾眼症)的治療藥的開發企業

  • AB2 Bio Ltd.
  • Akari Therapeutics, Plc
  • Allergan Plc
  • Circadian Technologies Limited
  • Delenex Therapeutics AG
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Huons Co., Ltd.
  • InSite Vision Incorporated
  • Kala Pharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Kukje Pharmaceutical Industry Co., Ltd.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lipicard Technologies Limited
  • Merck & Co., Inc.
  • Mimetogen Pharmaceuticals Inc.
  • Mitotech S.A.
  • Nanomerics Ltd
  • Neuroptis Biotech
  • Novaliq GmbH
  • Ocular Therapeutix, Inc.
  • Oculis ehf
  • OncoNOx ApS
  • 大塚集團
  • Parion Sciences, Inc.
  • PharmaReaserch Products Co., Ltd.
  • RegeneRx Biopharmaceuticals, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Samjin Pharmaceutical Co., Ltd.
  • 參天製藥
  • 生化學工業
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • TearSolutions, LLC.
  • Xigen SA

角膜乾燥症 (乾眼症) :治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

角膜乾燥症 (乾眼症) :最近的開發平台趨勢

角膜乾燥症 (乾眼症) :暫停中的計劃

角膜乾燥症 (乾眼症) :開發中止的產品

角膜乾燥症 (乾眼症) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9753IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS) or keratitis sicca, is a multifactorial disease of the tears and the ocular surface that results in discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Symptoms include eye fatigue, sensitivity to light, eye redness and stringy mucus in or around eyes. Risk factors include age, having laser eye surgery and taking medications that can cause dry eyes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 20, 9, 1, 24, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keratoconjunctivitis sicca (Dry Eye) - Overview
    • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development
    • Alcon Laboratories Inc
    • Aldeyra Therapeutics Inc
    • Allergan Plc
    • Ascendia Pharmaceuticals LLC
    • BioLineRx Ltd
    • Cambium Medical Technologies LLC
    • Chong Kun Dang Pharmaceutical Corp
    • Clementia Pharmaceuticals Inc
    • Dompe Farmaceutici SpA
    • Elasmogen Ltd
    • HanAll Biopharma Co Ltd
    • Herantis Pharma Plc
    • Huons Global Co Ltd
    • InSite Vision Inc
    • Kala Pharmaceuticals Inc
    • KPI Therapeutics Inc
    • Kukje Pharmaceutical Industry Co Ltd
    • Laboratoires Thea SA
    • Lipicard Technologies Ltd
    • Merck & Co Inc
    • Mitotech SA
    • Nanomerics Ltd
    • Nemus Bioscience Inc
    • Novaliq GmbH
    • Ocular Therapeutix Inc
    • Oculis ehf
    • OncoNOx ApS
    • Otsuka Holdings Co Ltd
    • Quorum Innovations LLC
    • Redwood Pharma AB
    • RegeneRx Biopharmaceuticals Inc
    • Samjin Pharm Co Ltd
    • Santen Pharmaceutical Co Ltd
    • Seikagaku Corp
    • Shire Plc
    • Sun Pharma Advanced Research Company Ltd
    • Sylentis SAU
    • TearSolutions LLC
    • TopiVert Ltd
    • Vanda Pharmaceuticals Inc
    • Xigen SA
  • Keratoconjunctivitis sicca (Dry Eye) - Drug Profiles
    • ADP-355 - Drug Profile
    • ADP-399 - Drug Profile
    • ADX-102 - Drug Profile
    • ADX-103 - Drug Profile
    • AGN-223575 - Drug Profile
    • AGN-232411 - Drug Profile
    • AL-41A1 - Drug Profile
    • AVA-3486 - Drug Profile
    • AVX-012 - Drug Profile
    • AX-1606 - Drug Profile
    • BL-1230 - Drug Profile
    • BRM-421 - Drug Profile
    • cenegermin - Drug Profile
    • cinhyaluronate sodium - Drug Profile
    • Cis-Urocanic Acid - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine SR - Drug Profile
    • dexamethasone acetate SR - Drug Profile
    • diclofenac sodium - Drug Profile
    • diquafosol tetrasodium - Drug Profile
    • Drug for Dry Eye - Drug Profile
    • ECF-843 - Drug Profile
    • Elate Ocular - Drug Profile
    • ELN-22 - Drug Profile
    • HL-036 - Drug Profile
    • HU-007 - Drug Profile
    • hyaluronate sodium - Drug Profile
    • ISV-101 - Drug Profile
    • K-089 - Drug Profile
    • KeraKlear - Drug Profile
    • KJ-14003 - Drug Profile
    • KJ-16001 - Drug Profile
    • KPI-190 - Drug Profile
    • Lacripep - Drug Profile
    • Leukothera - Drug Profile
    • lifitegrast - Drug Profile
    • LME-636 - Drug Profile
    • loteprednol etabonate - Drug Profile
    • LT-4003 - Drug Profile
    • NB-2222 - Drug Profile
    • Nov-03 - Drug Profile
    • Nov-07 - Drug Profile
    • OC-301 - Drug Profile
    • OCX-071 - Drug Profile
    • OTX-101 - Drug Profile
    • OX-1001 - Drug Profile
    • palovarotene - Drug Profile
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    • PPL-003 - Drug Profile
    • Protearin - Drug Profile
    • Qi-401 - Drug Profile
    • rebamipide - Drug Profile
    • RGN-259 - Drug Profile
    • RP-101 - Drug Profile
    • SA-001 - Drug Profile
    • SHP-659 - Drug Profile
    • SJP-002 - Drug Profile
    • solithromycin - Drug Profile
    • ST-266 - Drug Profile
    • Stem Cell Therapy for Cardiovascular, Central Nervous System, Mouth and Dental Disorders, Ophthalmology and Respiratory Disorders - Drug Profile
    • SYL-1001 - Drug Profile
    • tadekinig alfa - Drug Profile
    • TOP-1630 - Drug Profile
    • XG-104 - Drug Profile
    • zucapsaicin - Drug Profile
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects
  • Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products
  • Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Alcon Laboratories Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by BioLineRx Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Clementia Pharmaceuticals Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Elasmogen Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Global Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea SA, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech SA, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nemus Bioscience Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Redwood Pharma AB, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharm Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corp, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sylentis SAU, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions LLC, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Vanda Pharmaceuticals Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top